Get the Stockscreener App
310.67
20.88%
53.67
After Hours:
312.00
1.33
+0.43%
Insulet Corporation stock is traded at $310.67, with a volume of 3.21M.
It is up +20.88% in the last 24 hours and up +17.36% over the past month.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.
See More
Previous Close:
$257.00
Open:
$293.03
24h Volume:
3.21M
Relative Volume:
3.85
Market Cap:
$18.08B
Revenue:
$1.98B
Net Income/Loss:
$420.90M
P/E Ratio:
53.20
EPS:
5.84
Net Cash Flow:
$218.20M
1W Performance:
+20.88%
1M Performance:
+17.36%
6M Performance:
+15.92%
1Y Performance:
+75.00%
1-Day Range:
$293.03
$312.16
1-Week Range:
$252.88
$312.16
52-Week Range:
$160.19
$312.16
Insulet Corporation Stock (PODD) Company Profile
Name
Insulet Corporation
Sector
Industry
Phone
978-600-7000
Address
100 NAGOG PARK, ACTON, MA
Compare PODD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
310.67 | 18.08B | 1.98B | 420.90M | 218.20M | 5.84 |
|
ABT
Abbott Laboratories
|
133.24 | 231.09B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.86 | 155.24B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
380.92 | 144.54B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.48 | 108.82B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.68 | 44.31B | 5.54B | 4.18B | 623.10M | 7.00 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Mar-06-25 | Initiated | RBC Capital Mkts | Outperform |
| Nov-06-24 | Initiated | Bernstein | Outperform |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-07-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-21-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-04-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-02-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-21-23 | Upgrade | Citigroup | Neutral → Buy |
| Aug-21-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-11-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-19-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Jul-28-20 | Initiated | Wells Fargo | Overweight |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-03-20 | Initiated | BofA/Merrill | Neutral |
| Mar-31-20 | Downgrade | Berenberg | Buy → Hold |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-10-19 | Initiated | CFRA | Sell |
| Oct-23-19 | Initiated | Stifel | Hold |
| Oct-18-19 | Downgrade | Canaccord Genuity | Buy → Hold |
| Oct-14-19 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-04-19 | Downgrade | UBS | Buy → Neutral |
| Oct-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-06-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-10-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-06-19 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-20-18 | Initiated | Berenberg | Buy |
| Feb-22-18 | Reiterated | Barclays | Overweight |
| Jan-08-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Nov-03-17 | Upgrade | Canaccord Genuity | Hold → Buy |
| Sep-15-17 | Initiated | Barclays | Overweight |
View All
Insulet Corporation Stock (PODD) Latest News
Insulet Corporation (NASDAQ:PODD) Q1 2025 Earnings Call Transcript - Insider Monkey
Insulet (PODD) Sees Price Target Boost Amid Strong Sales Performance | PODD Stock News - GuruFocus
BTIG raises Insulet stock price target to $330, maintains Buy rating - Investing.com Nigeria
Insulet’s Earnings Call Reveals Strong Growth and Expansion - TipRanks
Piper Sandler maintains Overweight rating on Insulet stock By Investing.com - Investing.com Canada
Insulet Seeks $30M In Atty Fees, Costs After Trade Secret Win - Law360
U.S. Indexes Ended Friday Mixed As Insulet Led, Affirm Holdings Lagged - Barron's
New Insulet CEO Ashley McEvoy sets priorities - MedTech Dive
Sector Update: Health Care - marketscreener.com
Canaccord raises Insulet stock target to $331, maintains buy rating - Investing.com
Piper Sandler maintains Overweight rating on Insulet stock - Investing.com
Why Insulet (PODD) Stock Is Trading Up Today - Yahoo Finance
Insulet Stock Soars to Lead S&P 500 Gainers Friday - Investopedia
Insulet Q1 beat, Sweetgreen sinks on outlook, Wolfspeed drops - Yahoo Finance
Tesla, Insulet Surge Among Market Cap Stock Movers on Friday By Investing.com - Investing.com South Africa
Tesla, Insulet Surge Among Market Cap Stock Movers on Friday - Investing.com
Insulet (PODD) Price Target Raised by Oppenheimer Analyst | PODD Stock News - GuruFocus
Insulet (NasdaqGS:PODD) Announces $125M Buyback, Raises Revenue Guidance For 2025 - Yahoo Finance
Top Stock Movers Now: Tesla, Monster Beverage, Insulet, and More - Investopedia
Insulet Posts Strong Q1 Results, Raises Forecasts On Momentum In US And Abroad - Benzinga
Trade Desk, Insulet Surge in Friday’s Market Cap Stock Movers By Investing.com - Investing.com Nigeria
Trade Desk, Insulet Surge in Friday’s Market Cap Stock Movers - Investing.com Australia
Insulet Stock Is the Top S&P 500 Performer Today. Here’s Why. - MSN
Insulet Posts Upbeat Earnings, Joins Trade Desk, TransMedics Group, Tesla And Other Big Stocks Moving Higher On Friday - Benzinga
Piper Sandler on Insulet Corporation (PODD): 'Strong Update Across the Board' - StreetInsider
Canaccord raises Insulet stock target to $331, maintains buy rating By Investing.com - Investing.com India
BTIG Boosts Price Target for Insulet (PODD) After Strong Q1 Results | PODD Stock News - GuruFocus
Baird Adjusts Price Target on Insulet to $350 From $325, Maintains Outperform Rating - marketscreener.com
Insulet Corporation Exceeds Q1 CY2025 Revenue ExpectationsNews and Statistics - IndexBox
Insulet Corporation (PODD) PT Raised to $331 at Canaccord Genuity - StreetInsider
Insulet Corporation (PODD) PT Raised to $330 at BTIG - StreetInsider
Earnings call transcript: Insulet beats Q1 2025 forecasts, stock surges By Investing.com - Investing.com Nigeria
Insulet Corp (PODD) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion - GuruFocus
Insulet Corporation Reports Strong Q1 2025 Growth - TipRanks
Earnings call transcript: Insulet beats Q1 2025 forecasts, stock surges - Investing.com Australia
Insulet requests $30 million in attorneys fees after EOFlow trade secret injunction - MLex
Insulet’s (NASDAQ:PODD) Q1: Strong Sales, Stock Soars - Yahoo Finance
Insulet: Q1 Earnings Snapshot - MySA
Insulet's Strong Profit And Innovation Propel Shares Higher - Finimize
Insulet (PODD) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Insulet Q4 2024 slides: revenue tops $2.1B, margins expand as Type 2 diabetes push begins - Investing.com
Insulet (PODD) Q1 Earnings and Revenues Surpass Estimates - Yahoo Finance
Insulet Corp (PODD) Q1 2025 Earnings: Revenue Surges to $569M, Beating Estimates, EPS Falls Short at $0.50 - GuruFocus
Insulet Jumps After Beating Quarterly Forecasts, Raising 2025 Expectations - MSN
Insulet earnings beat by $0.23, revenue topped estimates By Investing.com - Investing.com South Africa
Insulet beats quarterly profit estimates on insulin pump demand - marketscreener.com
Insulet earnings beat by $0.23, revenue topped estimates - Investing.com Canada
Insulet Q1 Earnings Fall, Revenue Rises - marketscreener.com
Insulet (PODD) Reports Strong Q1 Revenue Beating Estimates | PODD Stock News - GuruFocus
Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency1) - Business Wire
Insulet Pursues EOFlow's Finances After $60M Ruling - Law360
Insulet Corporation Stock (PODD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):